270 related articles for article (PubMed ID: 7755503)
1. A recombinant vaccine for Lyme disease.
Wallich R; Kramer MD; Simon MM
Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
3. The outer surface protein A (OspA) of Borrelia burgdorferi: a vaccine candidate and bioactive mediator.
Kramer MD; Wallich R; Simon MM
Infection; 1996; 24(2):190-4. PubMed ID: 8740121
[TBL] [Abstract][Full Text] [Related]
4. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
Steere AC; Sikand VK; Meurice F; Parenti DL; Fikrig E; Schoen RT; Nowakowski J; Schmid CH; Laukamp S; Buscarino C; Krause DS
N Engl J Med; 1998 Jul; 339(4):209-15. PubMed ID: 9673298
[TBL] [Abstract][Full Text] [Related]
5. Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice.
Bockenstedt LK; Fikrig E; Barthold SW; Kantor FS; Flavell RA
J Immunol; 1993 Jul; 151(2):900-6. PubMed ID: 8335917
[TBL] [Abstract][Full Text] [Related]
6. T helper cell priming of mice to Borrelia burgdorferi OspA leads to induction of protective antibodies following experimental but not tick-borne infection.
Zhong W; Gern L; Kramer M; Wallich R; Simon MM
Eur J Immunol; 1997 Nov; 27(11):2942-7. PubMed ID: 9394822
[TBL] [Abstract][Full Text] [Related]
7. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
8. A new approach to a Lyme disease vaccine.
Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
[TBL] [Abstract][Full Text] [Related]
9. Murine Lyme borreliosis: route of inoculation determines immune response and infectivity.
Pachner AR; Delaney E; Ricalton NS
Reg Immunol; 1992; 4(6):345-51. PubMed ID: 1297405
[TBL] [Abstract][Full Text] [Related]
10. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
Beran J; De Clercq N; Dieussaert I; Van Hoecke C
Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
[TBL] [Abstract][Full Text] [Related]
11. The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine.
Wallich R; Kramer MD; Simon MM
Infection; 1996; 24(5):396-7. PubMed ID: 8923055
[No Abstract] [Full Text] [Related]
12. Protective immunity elicited by rBCG vaccines.
Stover CK; Bansal GP; Langerman S; Hanson MS
Dev Biol Stand; 1994; 82():163-70. PubMed ID: 7958471
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice.
Bockenstedt LK; Fikrig E; Barthold SW; Flavell RA; Kantor FS
J Immunol; 1996 Dec; 157(12):5496-502. PubMed ID: 8955199
[TBL] [Abstract][Full Text] [Related]
14. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.
Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM
Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917
[TBL] [Abstract][Full Text] [Related]
15. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi.
Langermann S; Palaszynski S; Sadziene A; Stover CK; Koenig S
Nature; 1994 Dec; 372(6506):552-5. PubMed ID: 7990928
[TBL] [Abstract][Full Text] [Related]
16. [Lyme borreliosis--vaccines in the "pipeline"].
Kramer M
MMW Fortschr Med; 1999 Jun; 141(25):52-3. PubMed ID: 10897909
[No Abstract] [Full Text] [Related]
17. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
Fawcett PT; Rose CD; Budd SM; Gibney KM
Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
[TBL] [Abstract][Full Text] [Related]
18. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA.
Ding W; Huang X; Yang X; Dunn JJ; Luft BJ; Koide S; Lawson CL
J Mol Biol; 2000 Oct; 302(5):1153-64. PubMed ID: 11183781
[TBL] [Abstract][Full Text] [Related]
19. Immunization against Lyme disease--an important first step.
Steigbigel RT; Benach JL
N Engl J Med; 1998 Jul; 339(4):263-4. PubMed ID: 9673306
[No Abstract] [Full Text] [Related]
20. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
